Loading
A phase 2 trial of Gamma Knife in Brain metastases, run by University of Alabama at Birmingham, completed.
Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases is a phase 2 interventional study registered as NCT00582075 by University of Alabama at Birmingham, with 25 participants recorded, started 2002-07 and reaching its primary completion in 2008-10. Interventions recorded: temozolomide. Conditions recorded: Cancer, Brain Metastases.
Linked to the technology Gamma Knife because the registry's title names it ("gamma knife") and Brain metastases among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
25 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2015-09-17), not from a publication
Sourcerange 11 to 104; Figures from the ClinicalTrials.gov results section (first posted 2015-09-17), not from a publication
SourceShares Gamma Knife and the tag pipeline.
Shares Gamma Knife and the tag pipeline.
Shares Temozolomide and the tag pipeline.
Shares Temozolomide and the tag pipeline.
Shares Temozolomide and the tag pipeline.
Shares Temozolomide and the tag pipeline.
Shares Temozolomide and the tag pipeline.
Shares Temozolomide and the tag pipeline.